Instructor in Medicine, Massachusetts General Hospital
Oncology
Dr. Steven J. Isakoff, MD
|
|
Give Review
Steven J. Isakoff is an expert in the field of Oncology. He went to NYU School of Medicine. Doctor Steven J. Isakoff, MD has written publications. He has 26 publications published with PubMed. The lastest paper is: 'Role of vascular density and normalization in response to neoadjuvant bevacizumab and chemotherapy in breast cancer patients.' Steven J. Isakoff is registered with Medicare.
Publications
- Comparison of the Genomic Landscape Between Primary Breast Cancer in African American Versus White Women and the Association of Racial Differences With Tumor Recurrence.
- Role of vascular density and normalization in response to neoadjuvant bevacizumab and chemotherapy in breast Cancer patients.
- Phase I/II dose-escalation study of PI3K inhibitors pilaralisib or voxtalisib in combination with letrozole in patients with hormone-receptor-positive and HER2-negativ...
- Randomized, phase II, placebo-controlled trial of onartuzumab and/or bevacizumab in combination with weekly paclitaxel in patients with metastatic triple-negative brea...
- Convergent loss of PTEN leads to clinical resistance to a PI(3)Kα inhibitor.
- Stand up to Cancer phase ib study of pan-phosphoinositide-3-kinase inhibitor buparlisib with letrozole in estrogen receptor-positive/human epidermal growth factor rece...
- Intermittent Letrozole Therapy for Metastatic Breast Cancer: Case Reports and Literature Review.
- Phase II Trial of Bicalutamide in Patients with Androgen Receptor-Positive, Estrogen Receptor-Negative Metastatic Breast Cancer.
- Neoadjuvant bevacizumab: surgical complications of mastectomy with and without reconstruction.
- Breast Cancer, Version 3.2013.
- A phase II study of bevacizumab in combination with vinorelbine and trastuzumab in HER2-positive metastatic breast Cancer.
- Residual Lymph Node Disease After Neoadjuvant Chemotherapy Predicts an Increased Risk of Lymphedema in Node-Positive Breast Cancer Patients.
- Proton Therapy for Breast Cancer After Mastectomy: Early Outcomes of a Prospective Clinical Trial.
- Circulating Breast tumor cells exhibit dynamic changes in epithelial and mesenchymal composition.
- Combination antiangiogenic therapy in advanced breast Cancer: a phase 1 trial of vandetanib, a VEGFR inhibitor, and metronomic chemotherapy, with correlative platelet ...
- Case records of the Massachusetts General Hospital. Case 27-2012. A 60-year-old woman with painful muscle spasms and hyperreflexia.
- Challenges to the Development of New Agents for Molecularly Defined Patient Subsets: Lessons From BRCA1/2-Associated Breast Cancer.
- Trastuzumab-DM1: building a chemotherapy-free road in the treatment of human epidermal growth factor receptor 2-positive breast Cancer.
- PARP Inhibition Outside of BRCA Mutation Carriers.
- Triple-negative breast Cancer: role of specific chemotherapy agents.
- A phase II study of oral enzastaurin in patients with metastatic breast Cancer previously treated with an anthracycline and a taxane containing regimen.
- Identification of novel pro-migratory, Cancer-associated genes using quantitative, microscopy-based screening.
- Functional proteomics approach to investigate the biological activities of cDNAs implicated in breast Cancer.
- Breast Cancer-associated PIK3CA mutations are oncogenic in mammary epithelial cells.
- A two-gene expression ratio predicts clinical outcome in breast Cancer patients treated with tamoxifen.
Schools
New York University
Brigham and Women39s Hospital
Dana Faber Cancer Institute
Procedures Preformed
- Thoracentesis
Conditions Treated
- Adrenal Gland Cancer
- Anal and Rectal Cancer
- Anemia
- Bile Duct Cancer
- View All
Doctors Specialties
- Medical Oncology
- Oncology
Accepted Insurances
Education
-
Brigham and Women's Hospital -
NYU School of Medicine
Hospital
-
Massachusetts General Hospital
Drug Facts
| NPI NUMBER | 1447205042 | |
| NPPES Provider LastName | ISAKOFF | |
| NPPES Provider FirstName | STEVEN | |
| NPPES Provider ZIPCode | 021142621 | |
| NPPES Provider State | MA | |
| Specialty Description | Hematology/Oncology | |
| Total Claim Count | 245.0 | |
| Distinct Opioid Count | 0.0 | |
| Opioid Claim Count | 0.0 | |
| Percent Opioid Claims | 0.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1447205042 |
| Last Name Of The Provider | ISAKOFF |
| First Name Of The Provider | STEVEN |
| View All |
Similar Doctors
|
|
Dr. Elizabeth Brem, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Andrew J. Aguirre, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. James W. Mier, MD
This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
|
Dr. Lakshmi Nayak, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Mary K. Buss, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Christopher J. Sweeney, MD |
|
|
Dr. Deborah Schrag, MD
This Doctor is OpenDoctor Recommended.
This doctor has more publications
|
|
|
Dr. Lori H. Pai, MD
This Doctor is OpenDoctor Recommended.
|